

Unaudited Condensed Consolidated Interim Financial Statements (Expressed in Canadian Dollars)

For the Three and Nine Month Periods Ended September 30, 2021 and 2020

# Condensed Consolidated Interim Statements of Financial Position

As at September 30, 2021 and December 31, 2020

(Unaudited - Expressed in Canadian Dollars)

			September 30,		December 31,
	Notes		2021		2020
ASSETS					
Current Assets					
Cash		\$	189,306	\$	136,553
Receivables			32,366		79,873
Due from related party	9		1,780,290		1,868,318
Prepaid expenses	6		274,936		291,000
Current portion of lease receivables	10		276,007		242,65
Fotal Current Assets		\$	2,552,905	\$	2,618,40
Non-Current Assets					
Property and Equipment	8	\$	911,634	\$	843,77
Lease receivables	10		2,790,180		2,999,16
Other assets	9		25,811		25,792
Fotal Non-Current Assets		\$	3,727,625	\$	3,868,733
FOTAL ASSETS		\$	6,280,530	\$	6,487,140
LIABILITIES					
Current Liabilities					
Accounts payable and accrued liabilities	8	\$	837,043	\$	650,578
Due to related parties	9		53,861		195,673
Current portion of lease obligations	10		288,227		254,98
Notes payable to related party	9		1,296,389		2,415,993
Derivative liability	11		352,536		362,758
Security deposit	9		15,289		15,278
Fotal Current Liabilities		\$	2,843,345	\$	3,895,263
Non-Current Liabilities					
Lease obligations	10		2,813,070		3,031,179
Fotal Non-Current Liabilities		\$	2,813,070	ć	3,031,179
FOTAL LIABILITIES		\$	5,656,415		6,926,442
					-,,
SHAREHOLDERS' EQUITY (DEFICIENCY)					
Share capital	11	\$	11,222,432	\$	7,087,003
Share-based payments reserve	12		508,190		138,33
Warrant reserve	11		16,780		38,07
Accumulated other comprehensive income			121,153		104,73
Accumulated deficit			(11,244,440)		(7,807,458
FOTAL SHAREHOLDERS' EQUITY (DEFICIENCY)		\$	624,115	\$	(439,302
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY)		\$	6,280,530	\$	6,487,14
Nature of operations and continuance of operations (note 1) Related party transactions (note 9)	Appro	ved	on behalf of the	Boa	ard by:
Subsequent events (note 15)	/c / Do	la a ut	Colwell	1.1	Chris Cooner

Subsequent events (note 15)

/s/ Robert Colwell	<u>/s/ Chris Cooper</u>
Director	Director

**Condensed Consolidated Interim Statements of Loss and Comprehensive Loss For the Three and Nine Month Periods Ended September 30, 2021 and 2020** (Unaudited - Expressed in Canadian Dollars Except Number of Shares)

			Three-month	ns pe	eriod ended		Nine-month	s pe	eriod ended
			Septe	mbe	er 30,		Septe	mb	er 30,
	Notes		2021		2020		2021		2020
Revenue	9	\$	621,131	\$	759,029	\$	1,850,673	\$	1,276,929
Expenses									
Communication		\$	40,070	\$	2,430	\$	88,617	\$	21,879
Consulting			45,975		35,988		134,452		94,456
Depreciation & Amortization	7		55,701		79,599		139,596		133,517
Director fees	9		6,000		6,000		18,000		18,000
Marketing			746,448		514,980		2,607,552		948,275
General office & administration			46,914		118,175		150,932		186,584
Utilities and property tax			87,979		-		283,631		-
Professional fees			62,078		114,244		282,703		396,166
Regulatory and filing fees			20,144		5,899		43,851		27,972
Share-based compensation	12		160,108		-		499,557		69,009
Wages and salaries	9		473,201		446,035		1,341,307		1,638,288
		\$	(1,744,618)	\$	(1,323,350)	\$	(5,590,198)	\$	(3,534,146)
Other Income / (Expenses)									
Interest income	9,10	\$	105,043	Ś	107,703	¢	268,687	Ś	182,534
Accretion expense	9	Ŷ	(36,310)	Ŷ	(84,023)	Ŷ	(130,696)	Ŷ	(145,354)
Foreign exchange loss	5		(133,897)		(4,467)		(92,207)		(17,126)
Gain / (Loss) on remeasurement of derivative	11		299,313		(1,107)		10,222		(17,120)
Other income	9		67,323		-		467,829		
Interest expense	10		(72,812)		(107,705)		(221,292)		(182,536)
Amortization of deferred gain	10		(72,012)		23,971		()		40,466
Net Loss for the Period		\$	(894,827)	\$	(628,842)	\$	(3,436,982)	\$	(2,379,233)
		•	( /- /	•	<u> </u>		(-, -, -, -, -, -, -, -, -, -, -, -, -, -		())1
Other Comprehensive Loss									
Items that may be subsequently reclassified to									
profit and loss									
Foreign currency translation adjustment		\$	23,161	Ş	(144,955)	\$	16,414	Ş	(144,955)
Total Comprehensive Loss for the Period		\$	(871,666)	\$	(773,797)	\$	(3,420,568)	\$	(2,524,188)
Basic and diluted loss per common share		\$	(0.02)	\$	(0.02)	\$	(0.07)	\$	(0.10)
Weighted average number of common shares									

## Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Deficiency)

For the Nine Month Period Ended September 30, 2021 and 2020

(Unaudited - Expressed in Canadian Dollars)

	Number of shares	Sh	are capital	Share bscription received	ck options reserve	Varrants reserve		Accumulated other omprehensive income	Α	ccumulated deficit	sha	Total areholder's equity
Balance - December 31, 2019	12,645,000	\$	736,251	\$ 40,000	\$ 34,338	\$ -		\$-	\$	(1,207,353)	\$	(396,764)
Shares issued for cash - private placement	7,759,271		1,939,817	(40,000)	-	-		-		-		1,899,817
Shares issued upon exercise of warrants and	4,658,220		1,191,813	-	(3 <i>,</i> 998)	-		-		-		1,187,815
agent units												
Share issue costs	-		(184,039)	-	42,073	-		-		-		(141,966)
Shares issued on Acquisition Transaction	9,000,000		2,250,000	-	-	-		-		-		2,250,000
Shares issued as signing bonus to New Leaf USA Executives	3,658,676		914,669	-	-	-		-		-		914,669
Fair value of warrants issued for Acquisition	-		-	-	649,440							649,440
Transaction												
Share-based payments	-		-	-	69,009	-		-		-		69,009
Net loss of the period	-		-	-	-	-		(144,955)		(2,379,233)		(2,524,188)
Balance - September 30, 2020	37,721,167	\$	6,848,511	\$ -	\$ 790,862	\$ -	\$	(144,955)	\$	(3,586,586)	\$	3,907,832
Balance - December 31, 2020	39,097,167	\$	7,087,003	\$ -	\$ 138,339	\$ 38,075	:	\$ 104,739	\$	(7,807,458)	\$	(439,302)
Shares issued upon exercise of warrants	11,907,417		3,841,974	-	-	(21,295)		-		-		3,820,679
Shares issued upon exercise of options	625,000		293,455	-	(129,706)	-		-		-		163,749
Share-based payments	-		-	-	499,557	-		-		-		499,557
Net loss for the period	-		-	-	-	-		16,414		(3,436,982)		(3,420,568)
Balance – September 30, 2021	51,629,584	\$	11,222,432	\$ -	\$ 508,190	\$ 16,780		\$ 121,153	\$	(11,244,440)	\$	624,115

## New Leaf Ventures, Inc. Condensed Consolidated Interim Statements of Cash Flows For the Nine Month Periods Ended September 30, 2021 and 2020 (Unaudited - Expressed in Canadian Dollars)

			Nine Months en	<mark>ded Se</mark>	ptember 30,
			2021		2020
	Notes		\$		\$
OPERATING ACTIVITES					
Net loss for the year		\$	(3,436,982)	\$	(2,379,233)
Non-cash items:					
Interest income	9,10	\$	(268 <i>,</i> 687)	\$	(182,534)
Interest expense	10		221,276		-
Accretion expense	9		130,696		145,354
Depreciation & Amortization	7		139,596		93,051
Foreign exchange			80,519		(6,642)
Share-based compensation	12		499,556		69,009
Gain / (loss) on remeasurement of derivative	11		(10,222)		-
Wages and salaries for shares			-		914,669
Changes in non-cash working capital items:					
Accounts receivable		\$	47,507	\$	(9,747)
Prepaids			16,070		-
Accounts payable and accrued liabilities			192,767		(153,687)
Due from related party	9		538,563		(962,415)
Due to related party	9		(140,701)		-
Other assets			666		-
Interest paid	10		(221,276)		-
Net cash used in operating activities		\$	(2,210,651)	\$	(2,472,175)
INVESTING ACTIVITIES					
Acquisition of property and equipment	7	\$	(205,655)	\$	(105,556)
Lease payments received	,	Ŷ	(203,033)	Ŷ	99,505
Net cash used by investing activities		\$	(205,655)	\$	(6,051)
FINANCING ACTIVITIES					
Proceeds from share issuance			-		2,976,416
Proceeds from exercise of warrants	11	\$	3,820,679	\$	
Proceeds from exercise of options	11	Ŷ	163,750	Ŷ	-
Repayment of note payable	9		(1,231,941)		(105,090)
Payment of lease obligations	10		(191,221)		(105,050)
Net cash provided by financing activities	10	\$	2,561,267	\$	2,816,236
Effect of foreign exchange rate fluctuation		Ý _	(92,207)	· ~	
Increase in cash in the year			(92,207) 52,753		- 338,010
Cash – beginning of the period		\$	<b>136,553</b>		80,150
		, –		_	
Cash – end of the period		ې	189,306	<u> </u>	418,160

Supplemental cash flow information (Note 14)

## **1. NATURE OF OPERATIONS AND CONTINUANCE OF OPERATIONS**

New Leaf Ventures Inc. (the "Company") was incorporated under the Business Corporations Act (British Columbia) on June 4, 2018. On September 13, 2019, the Company entered into the Share Purchase Agreement ("Acquisition Transaction") to purchase New Leaf USA Inc. ("New Leaf USA") and its subsidiaries (collectively the "New Leaf USA Entities"). As a result of the completion of the Acquisition Transaction on April 30, 2020, the New Leaf USA Entities are now the core business of the Company, and through which the Company will provide consulting services, real property, intellectual property and equipment for lease and enhanced ancillary services to New Leaf Enterprises, Inc., a Washington-based Tier 3 Producer/Processor focused on industrial-scale agronomy, processing, packaging, marketing and distributing cannabis and cannabis related products (the "License Holder"). The License Holder is considered a related party; refer to Note 5 for details on the Acquisition Transaction and Note 10 for details on the related party nature and transactions with the License Holder during the three and nine month period ended September 30, 2021.

The Company's head office, principal address and registered address and records office is 2200 HSBC Building, 885 West Georgia Street, Vancouver, British Columbia, V6C 3E8, Canada. The Company is listed on the Canadian Securities Exchange (the "CSE") under the ticker symbol "NLV.CN" and on the OTCQB, part of the OTC Markets Group, under the ticker "NLVVF".

These condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") on a going concern basis, which contemplates the realization of assets and discharge liabilities at their carrying values in the ordinary course of operations for the foreseeable future rather than through the process of forced liquidation.

During the nine months period ended September 30, 2021, the Company generated a net loss of \$3,436,982 (September 30, 2020 – net loss of \$2,379,233) and negative cash flows from operating activities of \$1,977,688 (September 30, 2020 – negative cash flows of \$2,472,175). As at September 30, 2021, the Company has an accumulated deficit of \$11,244,440 (December 31, 2020 – deficit of \$7,807,458) and a working capital deficiency of \$290,440 (December 31, 2020 – working capital deficiency \$1,276,856). As a result, the Company may not have sufficient capital to fund its current planned operations during the twelvemonth period subsequent to September 30, 2021.

These unaudited condensed consolidated Interim Financial Statements do not include any adjustments to the classification and amounts of assets and liabilities that may be required should the Company be unable to continue as a going concern. Different bases of measurement may be appropriate if the Company is not expected to continue operations for the foreseeable future. The Company's continuing operations as intended are dependent upon its ability to identify, evaluate and negotiate the acquisition of, participation in or interest in new assets or business opportunities, and its ability to attain profitable operations and generate funds therefrom, and raise equity capital or obtain the necessary financing sufficient to meet current and future obligations. These conditions indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern. Although the Company has been successful at raising funds in the past through the issuance of securities, it is uncertain whether it will be successful in doing so in the future

The COVID-19 pandemic continues to cause significant financial market and social dislocation. The situation is dynamic with various cities and countries around the world responding in different ways to address the outbreak. While the Company has experienced the impact of the COVID-19 outbreak on its operations, it has

continued to operate during the current pandemic. The Company will continue to monitor developments of the pandemic and continuously assess its potential further impact on its operations to prevent any disruptions. The Company has put in place multiple contingency plans to ensure its supply chain and general operations can be maintained with minimal disruption throughout the crisis. In the event of prolonged continuation of the pandemic, it is not clear what the potential impact may be on the Company's business, financial position and financial performance.

## 2. BASIS OF PRESENTATION AND STATEMENT OF COMPLIANCE

## Basis of presentation and statement of compliance

The unaudited condensed consolidated interim financial statements ("Interim Financial Statements") of the Company as at and for the three and nine month period ended September 30, 2021, including comparatives, have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board, applicable to the preparation of Interim Financial Statements as set out in International Accounting Standard 34 Interim Financial Reporting ("IAS 34").

The Company has consistently applied the same accounting policies throughout all periods presented. These Interim Financial Statements do not include all the disclosures required for a complete set of IFRS financial statements. Accordingly, they should be read in conjunction with the last audited consolidated annual financial statements and notes thereto for the year ended December 31, 2020 ("Annual Financial Statements"), which are available on SEDAR at www.sedar.com. Selected explanatory notes are included in the Interim Financial Statements to explain events and transactions that are significant to an understanding of the changes in the Company's financial position and performance since the last annual financial statements. These Interim Financial Statements were authorized for issue by the Audit Committee, on behalf of the Board of Directors, on November 29, 2021.

These Interim Financial Statements include the accounts of the Company and its subsidiaries with intercompany balances and transactions eliminated upon consolidation. The entities contained in the Interim Financial Statements are as follows:

Entity Name	Principal activity	Place of business and operations	Functional currency	Equity percentage
New Leaf Ventures, Inc. (the "Company")	Parent company	Canada	CAD \$	n/a
New Leaf USA, Inc. ("New Leaf USA")	Holding company for US Entities	United States	USD \$	100%
New Leaf Real Estate, LLC ("RealEstateCo")	Real property leasing	United States	USD \$	100%
New Leaf Equipment, LLC ("EquipmentCo")	Equipment leasing	United States	USD \$	100%
New Leaf IP, LLC ("IPCo")	Intellectual property licensing	United States	USD \$	100%
New Leaf Services LLC ("ServicesCo")	Management services	United States	USD \$	100%
New Leaf Hemp Company LLC ("HempCo")	Inactive	United States	USD \$	100%

## 2. BASIS OF PRESENTATION AND STATEMENT OF COMPLIANCE, CONTINUED

#### Use of Judgements, Estimates and Assumptions

The preparation of these Interim Financial Statements in accordance with IAS 34 requires management to use judgement and make estimates and assumptions that affect the application of accounting policies, the reported amounts of assets and liabilities at the date of the Interim Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. The judgements, estimates and associated assumptions are based on historical experience and other factors that management considers to be relevant and are subject to uncertainty. Judgements, estimates and underlying assumptions are reviewed on an ongoing basis, and revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Actual results could differ from these estimates due to changes in interest rates, foreign exchange rates, inflation, and economic conditions. The areas of significant judgement and estimation were identified in the Company's Annual Financial Statements for the year ended December 31, 2020.

## 3. SIGNIFICANT ACCOUNTING POLICIES

Significant accounting policies applied to these condensed consolidated Interim Financial Statements are the same as those applied to the Company's audited consolidated financial statements for the year ended December 31, 2020.

#### 4. SEGMENT REPORTING

The Company operates in one operating segment which provides management and ancillary services to a cannabis producer and processor based in the United States. For the purpose of segment reporting, the Company's Chief Executive Officer ("CEO") is the Chief Operating Decision Maker. The determination of the Company's operating segment is based on its organizational structure and how the information is reported to CEO on a regular basis. During the nine month period ended September 30, 2021, all the revenues from the Company were generated through intellectual property licensing, equipment leasing, and provision of management services to a single customer, the License Holder, who is located in the United States.

The Company's non-current assets by country are as follows:

	As of September 30, 2021	As of December 31, 2020
United States	\$ 3,727,625	\$ 3,868,733
Total non-current assets	\$ 3,727,625	\$ 3,868,733

All of the Company's non-current assets are held in the United States for the periods presented.

## 5. ACQUISITION OF NEW LEAF USA, INC.

On April 30, 2020, the Company completed their previously announced acquisition of New Leaf USA, Inc. and all of its wholly-owned subsidiaries. The acquisition provides the Company with immediate strategic access and footprint to the US cannabis market, specifically in the state of Washington. With the acquisition, the Company now has the ability to provide turnkey solutions to other licensed cannabis operators in the state of Washington. This is the first step in realizing management's vision for the Company to manage and invest in advanced stage operations in the North American Cannabis sector. In consideration for the acquisition, the Company issued the following:

- Issued 9,000,000 shares; and
- Issued 4,000,000 performance warrants ("Performance Warrants").

Each Performance Warrant entitles the holder to purchase one common share of the Company at the price of \$0.02 per common share for a period of three years, and will vest and become exercisable as follows:

- i. 2,000,000 Performance Warrants will vest and become exercisable if the Company or New Leaf Enterprises, Inc. (the "License Holder") achieves at least \$5,000,000 in annual gross revenue; and
- ii. 2,000,000 Performance Warrants will vest and become exercisable the Company or License Holder achieves at least \$7,500,000 in annual gross revenue.

In addition, New Leaf USA entered into employment agreements, pursuant to which Robert Colwell is appointed to act as Chief Executive Officer of New Leaf USA, and Boris Gorodnitsky is appointed to act as President of New Leaf USA, in each case, for a period of three years following the closing of the Acquisition Transaction, and pursuant to which the Company issued 1,829,338 common shares to each of Boris Gorodnitsky and Robert Colwell. The following table shows the final allocation of the purchase price to assets acquired and liabilities assumed, based on estimates of fair value, including a summary of the identifiable classes of consideration transferred, and amounts by category of assets acquired and liabilities assumed at the acquisition date:

	Final
Consideration transferred:	
Fair value of 9,000,000 common shares issued	\$ 2,250,000
Fair value of contingent consideration (i)	352,800
	\$ 2,602,800
Fair value of assets and liabilities recognized:	
Cash	\$ 3
Related party receivable (note 9)	584,555
Lease receivable	3,695,586
Equipment	896,289
Intangible assets	345,948
Lease deposits	28,179
Accounts payable	(420,334)
Capital lease obligations	(3,752,996)
Notes payable	(2,555,321)
Fair value of net assets acquired	\$ (1,178,091)
Goodwill (iii)	\$ 3,780,891

## 5. ACQUISITION OF NEW LEAF USA, INC. CONTINUED

- (i) The warrants were valued using the Black-Scholes Option Pricing model (note 12) and adjusted for the probability that revenue targets would be met over the vesting period. The Performance Warrants were accounted for under IFRS 9 Financial Instruments as a derivative financial liability as the instrument had an option to convert the Performance Warrants into shares of the Company for no consideration and which would result in a variable number of the Company's shares being issued on exercise (see note 12). The Performance Warrants are subsequently re-measured at each reporting date. As at September 30, 2021, the Performance Warrants were re-measured with a resulting gain on re-measurement of \$299,313 for the three months period ended September 30, 2021 recognized in profit and loss. For the nine months period ended September 30, 2021 a cumulative gain on re-measurement of \$10,222 has been recognized in profit and loss.
- (ii) There were no deferred tax liabilities identified as part of the Acquisition Transaction. Deferred tax assets were identified but were not recognized as its recoverability was not considered probable.
- (iii) During the year ended December 31, 2020 the Company performed an annual impairment test of goodwill and determine that the carrying value of the Company's total net assets exceeded the Company's value-in-use as at December 31, 2020. Subsequently, for the year ended December 31, 2020, the Company recorded an impairment loss of \$3,780,891 to reduce goodwill to \$nil. Refer to Note 8 of the Company's Annual Financial Statements for the year ended December 31, 2020

The intangibles recognized on the acquisition relate to existing contracts at acquisition date for equipment leasing and intellectual property licensing, as well as management services. New Leaf USA leases intellectual property ("IP agreement"), including, brand names and know-how specific to operations and management of cannabis production and processing. The License Holder pays an annual exclusivity fee of USD\$100,000 and the greater of \$1.07 per each unit sold or a quarterly license fee of USD\$150,000 for a period of six month, expiring October 1, 2020. New Leaf USA also leases cannabis production and processing equipment for a monthly leasing fee of USD\$6,000 per month. Both the equipment and IP agreement were extended by the License Holder for another six months on October 1, 2020. The Company is currently in the process of renegotiating the contracts at period end.

New Leaf USA provides various management services to the License Holder including office administration, human resource and staffing, marketing, and IT. For the provision of these services the License Holder pays a monthly services fee of USD\$100,000 a month. The management service agreement has a term of six months but automatically renews for an additional six months for up to four additional six-month renewal terms (from effective date August 1, 2019) unless sooner terminated. At the time of acquisition, the service agreement had three remaining six-month renewal terms available.

The goodwill recognized from the acquisition is attributable to synergies expected from integrating New Leaf USA into the Company's existing business. Another component of goodwill includes non-separable intangibles assets acquired, including know-how specific to operations and management of cannabis production and processing. The goodwill acquired is not deductible for tax purposes.

## 6. PREPAID EXPENSES

	September 30,	
	2021	December 31, 2020
Prepaid marketing expense \$	255,882	\$ 256,060
Prepaid accounting expense	-	30,000
Other prepaid expenses	19,054	4,946
Total prepaid expenses \$	274,936	\$ 291,006

## 7. PROPERTY AND EQUIPMENT

		Leasehold	
	Equipment	Improvements	Total
Cost			
As at December 31, 2019	\$ -	\$ -	\$ -
Acquisition transaction (note 5)	896,289	-	896,289
Additions	121,968	7,079	129,047
Currency translation adjustment	(75,904)	-	(75,904)
As at December 31, 2020	\$ 942,353	\$ 7,079	\$ 949,432
Additions	26,813	178,842	205,655
Currency translation adjustment	1,155	3,264	4,419
As at September 30, 2021	\$ 970,321	\$ 189,185	\$ 1,159,506
Accumulated Depreciation As at December 31, 2019	\$ -	\$ -	\$ -
As at December 31, 2019	\$ -	\$ -	\$ -
Additions	110,259	-	110,259
Currency translation adjustment	(4,602)	-	(4,602)
As at December 31, 2020	\$ 105,657	\$ -	\$ 105,657
Additions	122,612	16,984	139,596
Currency translation adjustment	2,309	310	2,619
As at September 30, 2021	\$ 230,578	\$ 17,294	\$ 247,872
Carrying Amount			
As at December 31, 2020	\$ 836,696	\$ 7,079	\$ 843,775
As at September 30, 2021	\$ 739,743	\$ 171,891	\$ 911,634

## 8. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

	September 30,	December 31,
	2021	2020
Trade payables	\$ 631,113	\$ 473,293
Accrued liabilities	205,930	177,285
Total accounts payable and accrued liabilities	\$ 837,043	\$ 650,578

## 9. RELATED PARTY TRANSACTIONS

Related party transactions consist of monthly transactions with the License Holder, who is considered a related party due to sharing common executives and key management with the Company. Key management include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole.

## (i) Transactions with the License Holder

During the three and nine-months period ended September 30, 2021 and 2020, the Company recognized the following revenues from the License Holder:

	Three m Septem	ns ended 30,		Nine I Septe	nths ended er 30,	
Transactions with License Holder	2021		2020		2021	2020
Equipment lease revenue	\$ 22,682	\$	23,978	\$	67,570	\$ 40,478
Service fee revenue	377,931		599,445		1,126,170	1,011,945
Variable IP licensing revenue	220,518		135,606		656,933	224,506
Total revenues from License Holder	\$ \$ 621,131 \$ 759,029 \$ 1,8					\$ 1,276,929

In addition, the Company also incurred the following transactions with the License Holder during the nine-month period ended September 30, 2021:

- a) Interest income on outstanding receivables relating to IP licensing revenues of \$38,332 (\$nil nine-months period September 30, 2020)
- b) Interest income on lease receivables of \$230,371 (\$182,534 nine-months period September 30, 2020) see Note 11
- c) Accretion expense on notes payables of \$130,696 (\$145,354 nine-months period September 30, 2020) see Note 10(i)
- d) Other income of \$467,829 (\$nil nine-months period September 30, 2020) relating to sub-lease operating expenses (utilities, property tax, insurance) that were incurred for by the Company and which are reimbursable by the License Holder

As at September 30, 2021 there was a balance of \$1,780,290 (December 31, 2020 - \$1,868,318) due from the License Holder to the Company related to the provision of services during nine-month period ended September 30, 2021 and for services previously rendered during the year ended December 31, 2020. In addition, there was a balance of \$53,861 (December 31, 2020 - \$195,673) due from the Company to the License Holder for reimbursable lease operating costs.

As at September 30, 2021, there was a balance of \$3,066,187 (December 31, 2020 - \$3,241,823) due from the License Holder to the Company related to the lease receivable. In addition, at September 30, 2021, there was a balance of \$15,289 (December 31, 2020 - \$15,278) due from the Company to the License Holder for a refundable security deposit.

As at September 30, 2021, there was a notes payable balance of \$1,296,389 (December 31, 2020 - \$2,415,991) due to the License Holder. The notes were recorded at fair value at initial recognition by

## 9. RELATED PARTY TRANSACTIONS CONTINUED

measuring the present-value of future note payments discounted at 12%. The notes are unsecured and bear a coupon interest rate of 2.72% per annum for a period of 27 months with a maturity date of August 1, 2022. The notes are to be repaid in eight, equal, quarterly instalments of US\$236,269. The notes payables were considered in default during the nine-months period ended September 30, 2021 due to missing of instalment payments. However, on May 10, 2021, the License Holder granted a waiver of default to EquipmentCo and IPCo in relation to missed payments. The License Holder waived its rights to demand immediate repayment for the entire principal and accrued interest outstanding on the notes. In addition, the License

Holder waives its right to increase the interest rate as permitted due to the occurrence of a default event. The waiver is effective for an indefinite period of time subject to the License Holder's discretion.

A continuity of notes payable for the nine-months period ended September 30, 2021 and year ended December 31, 2020 is as follows:

	Nine-month period ended September 30, 2021	Year ended December 31, 2020
Balance, beginning of period	\$ 2,415,991	\$ -
Acquisition transaction	-	2,555,321
Accretion expense	130,696	180,547
Payment	(1,231,941)	(99,908)
Currency translation adjustment	(18,357)	(219,969)
Balance, end of period	\$ 1,296,389	\$ 2,415,991
Less: Current portion of notes payable	\$ 996,319	\$ 2,415,991
Non-current portion of notes payable	\$ 300,070	\$ -

Repayments due on notes payable, including interest, for the next five years and thereafter are as follows:

2021	\$ 456,238
2022	903,092
2023	-
2024	-
2025	-
Thereafter	-
Total	\$ 1,359,330

## (ii) Transactions with other related parties

During the nine-months period ended September 30, 2021, the Company had the following transactions with a company controlled by a director of the Company:

(i) Interest expense on lease obligations of \$152,317 (Note 10)

## 9. RELATED PARTY TRANSACTIONS CONTINUED

As at September 30, 2021, there was a balance of \$25,811 (December 31, 2020 - \$25,792) due from the related party to the Company related to the prepaid rent. In addition, as at September 30, 2021 there was a balance of \$2,138,366 (December 31, 2020 - \$2,256,571) due from the Company to the related party related to the lease obligations

## (iii) Key Personnel Compensation

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company defines key management personnel as being the directors and key officers. The compensation awarded to key management personnel is as follows:

	Three months ended				Nine	Мо	nths ended
	September 30,					Sep	tember 30,
	2021		2020		2021		2020
Directors' fees	\$ 6,000	\$	6,000	\$	18,000	\$	18,000
Consulting fees <sup>(1)</sup>	33,000		27,000		99,000		61,000
Share-based payments <sup>(2)</sup>	9,701		-		244,704		69,009
Wages and salaries <sup>(3)</sup>	81,328		79,926		219,458		1,049,595
Total	\$ 130,029	\$	112,926	\$	581,162	\$	1,197,604

<sup>(1)</sup> During the nine-months ended September 30, 2021, the Company incurred consulting fees of \$54,000 (nine-months ended September 30, 2020 - \$36,000) to a company controlled by the CEO and consulting fees of \$45,000 (September 30, 2020 - \$25,000) to a company controlled by the CFO.

<sup>(2)</sup> Share-based payments relates to expenses accrued for options vested during the nine-month periods ended September 30, 2021 and 2020. These options were issued to directors and officers of the Company in 2021, 2020 and 2019.

<sup>(3)</sup> Wages and salaries consist of salaries to key executives for the nine-month periods ended September 30, 2021 and 2020.

## **10. LEASES**

On April 30, 2020, as part of the Acquisition Transaction (note 5), the Company acquired two building leases (the "Head Leases") currently housing an integrated cultivation facility in Seattle, Washington. Building Lease #1 is between RealEstateCo and a Washington based Company which is owned by a director of the Company. Building Lease #2 is between RealEstateCo and an arms-length Washington based Company. The Head Leases include an option to extend for a further 5 years until May 31, 2028, which the Company intends to exercise. Subsequently, the Company subleased the combined building space to the License Holder, a related party, with an option to extend for additional 5 years until May 31,

## **10. LEASES CONTINUED**

2028 (the sub-lease). Under IFRS 16, the Company classified the sub-lease as a finance lease because it is for the whole of the remaining term of the Head Lease.

There were no other leases identified, including short-term or low value leases, during the course of the nine-month period ended September 30, 2021.

## The Company as a Lessee

The facility is subleased to the License Holder with the Company maintaining the lease obligation. The Company used 9.5% interest rate, its incremental borrowing rate to calculate the present value of the lease payments as well as to calculate the monthly accretion expense.

The Company's lease obligations are as follows:

Lease Obligation	September 30, 2021	December 31, 2020
Balance, beginning of period \$	3,286,164	\$ -
Acquisition transaction (note 5)	-	3,752,996
Interest expense	221,276	220,420
Payment of lease obligations	(412,497)	(359,675)
Foreign exchange impact	6,354	(327,577)
Balance, end of period \$	3,101,297	\$ 3,286,164

Minimum lease payments are as follows:

Remaining minimum lease payments for each fiscal year:	
2021	\$ 139,991
2022	570,936
2023(i)	599,228
2024(i)	625,941
2025(i)	647,300
2026 and thereafter(i)	1,630,227
Total	\$ 4,213,623
Amount representing interest	(1,112,326)
Less: Current lease obligation	(288,227)
Long-term lease obligation	\$ 2,813,070

(i) The Company intends to exercise the extension option on the leases which will push the Head Lease end date out to May 31, 2028. However, the Company is only contractually obligated to remit Head Lease payments to May 31, 2023. The minimum Head Lease payments, as detailed in the above table, from May 31, 2023 onward illustrate the potential commitments upon exercise of the extension option.

## **10. LEASES CONTINUED**

#### The Company as a Lessor

Lease Receivable	September 30, 2021	December 31, 2020	
Balance, beginning of period	\$	3,241,823	\$ -
Acquisition transaction (note 5)		-	3,695,586
Interest income		230,371	229,007
Accrued sublease payments receivable		(412 <i>,</i> 497)	(359,675)
Foreign exchange impact		6,490	(323,095)
Balance, end of period	\$	3,066,187	\$ 3,241,823

(a) The Company fair-valued the acquired lease receivables by discounting the expected lease receivable payments over the life of the lease. The Company used an interest rate of 10.7% and 9.91%; the interest rate implicit in the lease.

Minimum lease payments receivable are as follows:

Remaining minimum lease payments receivable for each fiscal year	ar:	
2021		139,989
2022		570,936
2023(i)		599,228
2024(i)		625,941
2025(i)		647,300
2026 and thereafter(i)		1,656,039
Total	\$	4,239,433
Amount representing interest		(1,173,246)
Less: Current portion of lease receivables		(276,007)
Non-current lease receivables	\$	2,790,180

(i) The Company expects that the sublease tenant will exercise the extension option on the sublease, which will push the sublease end date out to May 31, 2028. However, the Company only has the contractual right to receive sublease payments up to May 31, 2023. The minimum sublease payments receivable, as detailed in the above table, from May 31, 2023 onward illustrate the potential commitments upon exercise of the extension option.

## **11. SHARE CAPITAL**

#### Authorized share capital

The Company's authorized to issue an unlimited number of preferred shares and common shares without par value.

As at September 30, 2021, 7,895,206 (December 31, 2020 – 12,126,755) total common shares outstanding were held in escrow.

## Issued share capital

## During the Nine-months period ended September 30, 2021:

During the Nine-months period ended September 30, 2021, the Company collected \$3,787,349 and \$163,750 in gross proceeds from the exercise of 11,774,097 share purchase warrants and 625,000 share options respectively. The warrant and option exercises resulted in the issuance of 12,399,097 common shares of the Company.

During the nine-months period ended September 30, 2021, the Company collected \$33,330 in gross process from the exercise of 133,320 Agent Warrants ("IPO Agent Warrants") which resulted in the issuance of 133,320 common shares and 66,660 share purchase warrants of the Company. Each share purchase warrant ("Additional Warrants") is exercisable into one common share of the Company at an exercise price of \$0.40 and expires on April 30, 2022. The exercise of the Agent Warrants also resulted in the reclassification of \$21,295 from warrant reserve to share capital.

## During the year ended December 31, 2020:

On April 30, 2020, the Company completed the first tranche of its initial public offering (the "Offering") of 4,768,871 units (the "Units") at a price of \$0.25 per Unit (the "Offering Price"), for aggregate gross proceeds of approximately \$1,192,217. Each Unit is comprised of one common share in the Company (a "Common Share") and one-half common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will be exercisable at a price of \$0.40 for a period of 24 months from the listing of the Common Shares on the Canadian Securities Exchange (the "CSE"), subject to early expiry (the "Early Expiry Event") if the closing price of the Common Shares on the CSE (or any equivalent exchange) is equal to or greater than \$0.60 per Common Share for a period of ten consecutive trading days.

In connection with the Offering, the Company paid cash commissions and corporate finance fees of \$128,355. The Company also granted 136,280 non-transferrable share purchase warrants (the "Agent Warrants"). Each Agent Warrant may be exercised into one unit (the "Agent Unit") at a price of \$0.25 until April 30, 2022, subject to an early expiry date upon the occurrence of the Early Expiry Event. Each Agent Unit consists of one common share and one-half of a common share purchase warrant (each whole warrant a "Warrant"). The fair value of the Agent Warrants was \$21,840, calculated using the Black-Scholes option pricing model. The amount was charged to share capital as non-cash share issue costs.

On April 30, 2020, the Company issued 9,000,000 common shares with assessed fair-value of \$2,250,000 in connection with the Acquisition Transaction (Note 5) that made up a portion of the purchase price. In addition, as part of the Acquisition Transaction, the Company issued a total of 3,658,676 common shares, with assessed fair-value of 914,669, to Boris Gorodnitsky and Robert Colwell as a signing bonus to become executives of New Leaf USA, Inc.

On June 2, 2020, the Company completed a second tranche of its initial public offering of 2,990,400 units at a price of \$0.25 per Unit, for aggregate gross proceeds of approximately \$747,600 (the "Second Tranche"). Each Unit is comprised of one common share in the Company and one-half common share

purchase warrant. Each Warrant will be exercisable at a price of \$0.40 until April 30, 2022 subject to early expiry on the Early Expiry Event.

In connection with the Second Tranche the Company paid a cash commission in the amount of \$9,600 as well reimbursement of expenses totalling \$4,012. In addition, the Company incurred \$105,507 of legal expense in connection with the Offering which was charged to share capital as share issuance costs.

The Company also granted 76,000 Agent Warrants. Each Agent Warrant may be exercised into one unit at a price of \$0.25 until April 30, 2022, subject to an early expiry date upon the occurrence of the Early Expiry Event. Each Agent Unit consists of one common share and one-half of a common share purchase warrant. The fair value of the Agent Warrants was \$20,233, calculated using the Black-Scholes option pricing model. The amount was charged to share capital as non-cash share issue costs.

During the twelve months ended December 31, 2020, the Company raised \$1,531,815 in gross proceeds from the exercise of 6,005,000 warrants and 29,220 Agent Warrants. Upon exercise of the Agent Warrants, the Company transferred \$3,997 from warrant reserve to share capital, representing the fair value of the Agent Warrants. In addition, the Company issued 14,610 warrants with an exercise price of \$0.40, expiring on April 30, 2022 as a result of the exercise of the Agent Warrants.

## <u>Warrants</u>

The changes in warrants during the nine months period ended September 30, 2021 and the year ended December 31, 2020 are as follows:

		We	eighted Average
	Number of Warrants		<b>Exercise Price</b>
Balance, December 31, 2019	12,000,000	\$	0.25
Granted (i)(ii)(iii)	20,106,526		0.32
Exercised	(6,034,220)		0.25
Balance, December 31, 2020	26,072,306	\$	0.31
Granted	66,660		0.40
Exercised	(11,907,417)		0.32
Expired (iv)	(701,809)		0.40
Balance, September 30, 2021	13,529,740	\$	0.30

(i) On June 19, 2020, the Company decided to amend the terms (the "Amendment") of an aggregate of 12,000,000 outstanding common share purchase warrants previously issued by the Company. The 12,000,000 warrants were previously exercisable to acquire common shares of the Company at a price of \$0.05 until February 26, 2021. Under the Amendment, the exercise price of the Warrants was increased to \$0.25. There was no increase to the incremental fair value of the warrants as a result of these modifications. As compensation to allow for the repricing of the share purchase warrants, the Company issued 12,000,000 additional share purchase warrants with expiry date of June 19, 2022 and an exercise

price of \$0.40. There was no increase to the value of the warrant reserve for the compensatory warrants as it was offset by a corresponding increase to warrant issuance costs resulting in a \$nil impact on the Company's equity position.

(ii) As part of the acquisition transaction (note 5), the Company issued 4,000,000 Performance Warrants. The Performance Warrants are subject to vesting conditions based on revenue targets for either the Company or the License Holder. Each Performance Warrant entitles the holder to purchase one Class A common share of the Company at an exercise price of \$0.02. Assuming vesting conditions are met, the holder can elect to exercise the Performance Warrants, on a net settlement basis based on the fair market value of the shares on the exercise date

The Performance Warrants were assessed to be a derivative liability in accordance with IFRS 9 and were initially measured at fair value of \$352,800 using the Black-Scholes option pricing model. Subsequent to initial recognition, the Performance Warrants were re-measured at fair value using the following input assumptions:

	Nine-month period ended September 30,	Year ended
	2021	December 31, 2020
Share price at grant date (\$)	\$ 0.25	\$ 0.25
Exercise Price	\$ 0.02	\$ 0.02
Expected annual volatility	158%	116.33%
Expected life (in years)	1.58	3.0
Expected dividend yield	0%	0%
Risk-free interest rate	0.53%	0.28%
Fair value per warrant	\$0.24	\$0.24

A cumulative gain on re-measurement of \$10,223 (year ended December 31, 2020 – loss of \$9,958) was recognized in profit and loss for the nine-months period ended September 30, 2021.

(iii) As part of the initial public offering closed during the year ended December 31, 2020, the Company issued 212,281 agent warrants which were fair-valued using the Black-Scholes option pricing model and the following weighted average input assumptions:

	Year ended
	December 31, 2020
Share price at grant date (\$)	\$ 0.30
Exercise Price	\$ 0.25
Expected annual volatility	106%
Expected life (in years)	1.97
Expected dividend yield	0%
Risk-free interest rate	0.29%
Fair value per warrant	\$0.17

(iv) On March 2, 2021, the Company accelerated the expiry of share purchase warrants ("IPO warrants") originally granted as part the Company's initial public offering on April 30, 2020. The IPO warrants were subject to early expiry (the "Early Expiry Event") if the closing price of the Common Shares on the CSE (or any equivalent exchange) was equal to or greater than \$0.60 per Common Share for a period of ten consecutive trading days. The Company determined that as of start of day March 2, 2021 (the "Assessment Date"), that the Company's Common Share price had been trading at, or greater than, \$0.60 for the last 10 consecutive trading days. As a result, the warrants were accelerated to expire within 30 days from and including the Assessment Date. The accelerated expiry date was March 31, 2021.

Number of Warrants	Number of Warrants				Weighted Average Remaining Contractual Life in
Outstanding	Exercisable	Exerci	se Price	Expiry Date	Years
49,740	49,740		0.25	April 30, 2022	0.58
9,480,000	9,480,000		0.40	September 19,2022	0.72
4,000,000	-		0.02	April 30, 2023	1.58
13,529,740	9,529,740	\$	0.29		0.97

As at September 30, 2021, warrants outstanding are as follows:

# 12. SHARE-BASED COMPENSATION

## Equity incentive plan

The Company implemented an Equity Incentive Plan (the "EIP") which provides for the grant to eligible directors and employees (including officers) of share options and Restricted Share Rights ("RSR"). The EIP also provides for the grant to eligible directors of Deferred Share Units ("DSU") which the directors are entitled to redeem for 90 days following retirement or termination from the Board of the Company (the "Board"). The aggregate number of Common Shares that may be subject to issuance under the Equity Incentive Plan, together with any other securities-based compensation arrangements of the Corporation, shall not exceed 15% of the Corporation's issued and outstanding share capital from time to time.

Options are exercisable for a period of five years from the date the Option is granted or such greater or lesser period as determined by the Board. Options may be earlier terminated in the event of death or termination of employment or appointment. Vesting of Options is determined by the Board. Failing a specific vesting determination by the Board, Options automatically become exercisable incrementally over a period of eighteen months from the date of grant, as to: (i) 25% of the total number of shares under Option immediately upon the date of grant; and (ii) at each six-month interval thereafter, an additional 25% of the total number of shares under Option will be exercisable. The right to exercise an Option may be accelerated in the event a takeover bid in respect of the Common Shares is made.

## **12. SHARE-BASED COMPENSATION CONTINUED**

Concurrent with the granting of the RSR, the Board shall determine the period of time during which the RSR is not vested and the holder of such RSR remains ineligible to receive Common Shares. Such period of time may be reduced or eliminated from time to time for any reason as determined by the Board. Once the RSR vests, the RSR is automatically settled through the issuance of an equivalent number of underlying Common Shares as RSRs held.

DSUs are redeemable during the period commencing on the business day immediately following the date such director ceases to hold any directorship and ending on the 90<sup>th</sup> day following such date by providing written notice of redemption to the Corporation. Upon redemption, the director shall be entitled to receive the number of Common Shares equal to the number of DSUs in the director's account. If the director ceases to hold office during a year where DSUs have been granted in advance of being earned and they have not held office for the entire year, the director will only be entitled to a pro-rated issuance of shares.

The Company's recorded share-based compensation for the three-month periods ended September 30, 2021 and 2020 comprised the following:

	Three months ended				Nine Mo	onth	s ended
	September 30,		September 30,		September 30,		September
	2021		2020		2021		30, 2020
Stock Options (a)	\$ 160,108	\$	-	\$	499,557	\$	69,009

## (a) Share options

The number of options, the exercise price per option, the vesting period and any other terms and conditions of options granted from time to time pursuant to the EIP, are determined by the Board at the time of the grant, subject to the defined parameters of the EIP. Movements in the number of stock options outstanding and their related weighted average exercise prices are as follows:

	Number of Options	Aver	Weighted age Exercise Price
Balance, December 31, 2019	500,000	\$	0.25
Granted	1,225,000		0.34
Balance, December 31, 2020	1,725,000	\$	0.31
Granted	1,375,000		0.28
Exercised	(625,000)		0.26
Balance, September 30, 2021	2,475,000	\$	0.31

The exercise of stock options in the period resulted in a transfer from stock option reserve to share capital of \$129,706 for the nine-months ended September 30, 2021.

## **12. SHARE-BASED COMPENSATION CONTINUED**

The Company fair valued the options using the Black-Scholes option pricing model with the following inputs:

	Nine-month period	
	ended September 30,	Year ended
	2021	December 31, 2020
Share price at grant date (\$)	\$ 0.28	\$ 0.34
Exercise Price	\$ 0.28	\$ 0.34
Expected annual volatility	129% - 133%	138%
Expected life (in years)	5	5
Expected dividend yield	0%	0%
Risk-free interest rate	0.42% - 0.92%	0.27%
Fair value per option	\$0.24	\$0.30

The risk-free interest rate is based on the yield of a risk-free Canadian government security with a maturity equal to the expected life of the options from the date of the grant. The assumption of expected volatility is based on the average historical volatility of comparable companies for the period immediately preceding the option grant. The Company does not anticipate paying any cash dividends in the foreseeable future and, therefore, uses an expected dividend yield of zero in the option-pricing model.

Total fair value of stock options granted during the nine-months period ended September 30, 2021 was \$330,625 (nine-months period ended September 30, 2020 - \$Nil).

Number of Options	Number of Options				Weighted Average Remaining Contractual Life in
Outstanding	Exercisable	Exer	cise Price	Expiry Date	Years
125,000	125,000		0.25	November 14, 2024	3.13
625,000	625,000		0.28	January 15, 2026	4.30
500,000	500,000		0.28	September 22, 2026	4.98
1,225,000	230,000		0.34	November 10, 2031	10.12
2,475,000	1,480,000	\$	0.31		7.26

Stock options outstanding and exercisable at September 30, 2021 are as follows:

## (b) Restricted Share Rights ("RSR")

RSR's granted by the Company provides the recipient with the right to receive common shares of the Company as a discretionary payment in consideration of past services or as an incentive for future services. The terms including the vesting period of the RSRs are determined at the sole discretion of the Board.

During the nine-month period ended September 30, 2021 and year-ended December 31, 2020, the Company did not issue any RSRs and there are no RSRs outstanding.

## **12. SHARE-BASED COMPENSATION CONTINUED**

## (c) Deferred Share Units ("DSU")

The EIP authorizes the Board to grant DSUs, in its sole and absolute discretion in a lump sum amount or on regular intervals to eligible directors of the Company.

During the nine-month period ended September 30, 2021 and year-ended December 31, 2020, the Company did not issue any DSUs and there are no DSUs outstanding.

## **13. FINANCIAL INSTRUMENTS**

#### Fair value

The carrying values of cash, receivables, accounts payable and accrued liabilities and due to/from related parties approximate their fair values due to the relatively short period to maturity of those financial instruments. The fair value of notes payable to related parties and lease receivable from related parties approximate their carrying value as they were fair valued as part of the acquisition purchase price allocation using a market rate of interest. Derivative warrant liability is carried at fair value and revalued at each reporting date.

Financial instruments recorded at fair value on the statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of the fair value hierarchy are as follows:

- Level 1: Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- Level 2: Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- Level 3: Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

Fair value estimates are made at a specific point in time, based on relevant market information and information about the financial instruments. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Change in assumptions could significantly affect the estimates.

## **13. FINANCIAL INSTRUMENTS CONTINUED**

The following table summarizes the classification of the Company's financial instruments under IFRS 9:

FINANCIAL ASSETS	\$
Cash	Fair Value Through Profit and Loss
Receivables	Amortized cost
Due from related party	Amortized cost
Lease receivable	Amortized cost
FINANCIAL LIABILITIES	
Accounts payable and accrual liabilities	Amortized cost
Due to related party	Amortized cost
Notes payable	Amortized cost
Derivative liability	Fair Value Through Profit and Loss

#### Credit risk

Credit risk is the risk of loss associated with counterparty's inability to fulfill its payment obligations. The Company's credit risk is primarily attributable to cash, receivables, and amounts due from related parties. Receivables are primarily related to GST receivable and other receivable balances. Given the GST is payable by the government of Canada, management feels there is minimal credit risk associated with this receivable balance. Similarly, management feels there is minimal risk of non-collection since License Holder has been paying its obligations to the Company. The Company does not have significant credit risk with respect to customers. The Company's maximum credit risk exposure is equivalent to the carrying value of these instruments.

## Liquidity risk

The Company manages liquidity risk by maintaining adequate cash balances to meet short and long-term business requirements. As at September 30, 2021, all of the Company's financial liabilities, except for its warrant derivative liability and notes payable, have maturities less than one year. As at September 30, 2021, the Company had cash of \$189,306 (December 31, 2020 – \$136,553) and a working capital deficiency of \$290,440 (December 31, 2020 – working capital deficiency of \$1,276,856). Refer to note 1 for further discussion regarding going concern.

## Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company holds cash in accounts with variable interest rates, and currently does not carry variable interest-bearing debt. It is management's opinion that the Company is not exposed to significant interest rate risk.

## Foreign currency risk

Foreign currency risk is defined as the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company maintains financial instruments and enters into transactions denominated in foreign currencies, principally in USD, exposing the Company to fluctuating balances and cash flows due to various in foreign exchange rates. The Company has not entered into any foreign currency contracts to mitigate this risk. The CAD equivalent carrying amounts of the Company's USD denominated monetary assets and monetary liabilities is as follows:

	As of September 30,	
	2021	As of December 31, 2020
ASSETS	\$	\$
Cash	189,306	-
Due from related party	1,780,290	1,868,318
LIABILITIES		
Accounts payable and accrual liabilities	837,043	230,189
Due to related party	53,861	195,673
Notes payable	1,296,389	2,415,991

Assuming all other variables remain constant, a fluctuation of +/-5.0% in the exchange rate between CAD and USD would impact the comprehensive loss for the period by approximately \$2,977 (2020 - \$50,894).

## 14. SUPPLEMENTAL CASH FLOW INFORMATION

The following are non-cash investing and financing activities that occurred during the period ended September 30, 2021 and September 30, 2020

	September 30,	September 30,
	2021	2020
Movement from reserve on exercise of options	\$ 129,706	\$ -
Movement from reserve on exercise of warrants	21,295	3,997
Accrued sublease payments receivable	244,657	292,310
Share subscription redeemed	-	40,000
Share issuance costs – agent warrants	-	42,072
Prepaid share issuance costs	-	30,750
Acquisition of New Leaf USA	-	2,602,800

During the period ended September 30, 2021, the Company made cash payments of \$nil related to taxes (September 30, 2020 - \$nil) and \$187,344 related to interest (September 30, 2020 - \$118,662).

## **15. SUBSEQUENT EVENTS**

On November 2, 2021, pursuant to its base shelf prospectus dated July 26, 2021 and the prospectus supplement dated October 27 2021, the Company completed a public offering consisting of 6,000,000 units of the Company (the "Units") at a price of \$0.25 per Unit (the "Offering Price"), for aggregate gross proceeds of \$1,500,000. Each Unit is comprised of one (1) common share of the Company (a "Common Share") and one half (1/2) common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will be exercisable at a price of \$0.40 until November 1, 2023 (the "Expiry Date") subject to acceleration. If, during the life of the Warrants, the closing price of the Common Shares as quoted on the Canadian Securities Exchange is equal to or exceeds \$0.60 per Common Share for any 10 consecutive trading days, the Company may provide notice to the holders of the Warrants by issuance of a news release that the expiry date of the Warrants will be accelerated to the 30th day after the date on which the Company issues such news release.

In connection with the public offering and pursuant to an agency agreement dated October 27, 2021, between the Company and Research Capital Corporation (the "Agent"), the Agent acted as agent for the offering, and received a cash commission in the amount of \$105,000 in connection with the offering from certain purchasers of the Units (the "Purchasers"). The Company also issued 420,000 non-transferrable share purchase warrants (the "Agent Warrants") to the Agent and members of its selling group. Each Agent Warrant will entitle the holder thereof to purchase one Unit (an "Agent Unit") at an exercise price of \$0.25 until the Expiry Date. Each Agent Unit consists of one Common Share and one-half of one warrant (each whole warrant, an "Agent Unit Warrant"). Each Agent Unit Warrant will entitle the holder thereof to purchase one Common Share on the same terms and conditions as the Warrants.